JNJ multiple myeloma therapy outperforms standard of care (NYSE:JNJ)

Hailshadow

Johnson & Johnson (NYSE:JNJ) announced Tuesday that its FDA-approved multiple myeloma therapy Darzalex Faspro in a combination regimen cut the risk of disease progression or death by 58% compared to standard of care in a Phase 3 study.

A subcutaneouslyGMAB

CareJNJmultiplemyelomaNYSEJNJoutperformsStandardtherapy
Comments (0)
Add Comment